Gözde TAHTACI, Derya PEHLİVAN, Özlem Şahin BALÇIK, Ali KOŞAR

İntravenöz demir tedavisinin etkinliğive yan etkileri

Amaç: Bu çalışmada demir eksikliği anemisi olan hastalarda intravenöz demir sükroz tedavisinin etkinliğini ve tedaviye bağlı oluşan komplikasyonların saptanmasını amaçladık. Materyal ve Metot: Demir eksikliği anemisi nedeniyle intravenöz demir sükroz tedavisi uygulanan 79 hastanın verileri retrospektif olarak tarandı. İntravenöz demir sükroz tedavisi öncesi ve sonrasına ait kan sayımı, ferritin düzeyleri ve tedavi sırasında gelişen kompli-kasyonlar kaydedildi. Bulgular: Olguların uygulama öncesi ve uygulamadan dört hafta sonraki hemoglobin, MCV, RDW ve ferritin değerlerinde istatistiksel olarak anlamlı artış saptandı (p

The efficacy and side effects of intravenous iron therapy

Objective: In this study we aimed to determine the efficacy and complications due to intravenous iron sucrose therapy in patients with iron deficiency anemia. Material and Method: Data of 79 patients with iron deficiency anemia who were given intravenous iron sucrose therapy were retrospectively reviewed. Complete blood count and ferritin levels before and after treatment and complications were recorded. Results: Statistically significant difference was obtained in term haemoglobin, MCV, RDW and ferritin levels before and four weeks after the administration of intravenous iron therapy (p<0.001). During treatment rash (3%), arthralgia (3%), widespread body pain (5%), anaphylactic reaction (3%), and arthritis (1%) were observed. Conclusion: Intravenous administration of iron sucrose is efficient and safe choice of treatment when this drug is used in accurate dosages and correct indications.

PDF

___

1. WHO. Worldwide prevalence of anaemia 19932005: WHO global database on anaemia. Geneva: World Health Organization; 2008
2. Liua K, Kaffesb AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. European Journal of Gastroenterology & Hepatology 2012;24:10916.
3. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000;46(Suppl 34):IV1IV5.
4. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010; 16(22):2720-5.
5. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohns disease. Aliment Pharmacol Ther 2006;24:150723.
6. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:37882.
7. Chandler G, Harchowal J, MacDougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:98891.
8. Grau PW: Intravenous iron therapy. In: Beaumont C, Beris P, Beuzard Y, Brugnara C (eds) Disorders of iron homeostasis, erythrocytes, erythropoiesis. Paris, European School of Haematology 2006;420-34.
9. Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion. 2008;48(5):988-1000.
10. Munoz M, Breymann C, Garcia-Erce, Gómez-Ramírez S, Comin J, Bisbe E, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008;95:3501.